Protecting the Gut Microbiome

Synthetic Biologics is developing cutting-edge therapeutics to treat pathogen-specific diseases. 

Our two leading candidates are:
SYN-004 (ribaxamase) to prevent C. difficile infection and antibiotic-associated diarrhea
SYN-010 to treat irritable bowel syndrome with constipation (IBS-C)

View SYN-004 (ribaxamase) View SYN-010

About Synthetic Biologics

We are a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. Founded in 2001, Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN".

Learn More

Leadership

Our experienced management team has an extensive clinical and commercial track record.

Latest News

Jan 18, 2017 • 4:09pm EST

Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA

-- Enrollment in SYN-010 Pivotal Trial Will Be Open to All IBS-C Patients -- ROCKVILLE, Md., Jan. 18, 2017 /PRNewswire/ -- 

View all news

Investor Relations

Symbol NYSE MKT: SYN
Price
Change
Volume
Day Low/High
52 Week Low/High